Investigation of nanomaterial disposition and fate in the body is critical before such material can be translated into clinical application. Herein a new macrocyclic ligand−⁶⁴Cu²⁺ complex was synthesized and used to label dextran-coated silicon quantum dots (QD), with an average hydrodynamic diameter of 15.1 ± 7.6 nm. The chelate showed exceptional stability, demonstrated by no loss radiolabel under a ligand competition reaction with EDTA. The QDs’ biodistribution in mice was quantitatively evaluated by in vivo positron emission tomography (PET) imaging and ex vivo gamma counting. Results showed that they were excreted via renal filtration shortly postinjection and also accumulated in the liver.

Hydrogen capped silicon nanoparticles with strong blue photoluminescence were synthesized by the metathesis reaction of sodium silicide, NaSi, with NH4Br. The hydrogen capped Si nanoparticles were further terminated with octyl groups and then coated with a polymer to render them water soluble. The nanoparticles were characterized by TEM, FT-IR, UV-VIS absorption, and photoluminescence. The Si nanoparticles were shown to have an average diameter of 3.9 ±1.3 nm and exhibited room-temperature photoluminescence with a peak maximum at 438 nm with a quantum efficiency of 32% in hexane and 18% in water; the emission was stable in ambient air for up to 2 months. These nanoparticles could hold great potential as a non-heavy element containing quantum dot for applications in biology.